High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris. Issue 1 (23rd December 2020)
- Record Type:
- Journal Article
- Title:
- High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris. Issue 1 (23rd December 2020)
- Main Title:
- High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris
- Authors:
- Anna, François
Goyard, Sophie
Lalanne, Ana Ines
Nevo, Fabien
Gransagne, Marion
Souque, Philippe
Louis, Delphine
Gillon, Véronique
Turbiez, Isabelle
Bidard, François‐Clément
Gobillion, Aline
Savignoni, Alexia
Guillot‐Delost, Maude
Dejardin, François
Dufour, Evelyne
Petres, Stéphane
Richard‐Le Goff, Odile
Choucha, Zaineb
Helynck, Olivier
Janin, Yves L.
Escriou, Nicolas
Charneau, Pierre
Perez, Franck
Rose, Thierry
Lantz, Olivier - Abstract:
- Abstract: Although the COVID‐19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Using high‐throughput methods, we assessed herein the serological response against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) of 1847 participants working in three sites of an institution in Paris conurbation. In May–July 2020, 11% (95% confidence interval [CI]: 9.7–12.6) of serums were positive for IgG against the SARS‐CoV‐2 N and S proteins, and 9.5% (95% CI: 8.2–11.0) were neutralizer in pseudo‐typed virus assays. The prevalence of seroconversion was 11.6% (95% CI: 10.2–13.2) when considering positivity in at least one assay. In 5% of RT‐qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia (loss of smell) and ageusia (loss of taste) occurred in 52% of the IgG‐positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia–ageusia cases were seronegative, suggesting that the true prevalence of infection may have reached 16.6%. In sera obtained 4–8 weeks after the first sampling, anti‐N and anti‐S IgG titers and neutralization activity in pseudo‐virus assay declined by 31%, 17%, and 53%, resulting thus in half‐life of 35, 87, and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation of the true prevalence of infection.Abstract: Although the COVID‐19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Using high‐throughput methods, we assessed herein the serological response against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) of 1847 participants working in three sites of an institution in Paris conurbation. In May–July 2020, 11% (95% confidence interval [CI]: 9.7–12.6) of serums were positive for IgG against the SARS‐CoV‐2 N and S proteins, and 9.5% (95% CI: 8.2–11.0) were neutralizer in pseudo‐typed virus assays. The prevalence of seroconversion was 11.6% (95% CI: 10.2–13.2) when considering positivity in at least one assay. In 5% of RT‐qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia (loss of smell) and ageusia (loss of taste) occurred in 52% of the IgG‐positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia–ageusia cases were seronegative, suggesting that the true prevalence of infection may have reached 16.6%. In sera obtained 4–8 weeks after the first sampling, anti‐N and anti‐S IgG titers and neutralization activity in pseudo‐virus assay declined by 31%, 17%, and 53%, resulting thus in half‐life of 35, 87, and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation of the true prevalence of infection. Abstract : In May 2020, 11% of workers at Institut Curie living in Paris conurbation were seropositive and 9.5% had detectable but short‐lived neutralizing antibodies of SARS‐CoV‐2. Some 21% of these neutralizing sera actually belong to asymptomatic individuals. Only 2% of the PCR‐detected infections had not been followed by humoral immune response. … (more)
- Is Part Of:
- European journal of immunology. Volume 51:Issue 1(2021)
- Journal:
- European journal of immunology
- Issue:
- Volume 51:Issue 1(2021)
- Issue Display:
- Volume 51, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 51
- Issue:
- 1
- Issue Sort Value:
- 2021-0051-0001-0000
- Page Start:
- 180
- Page End:
- 190
- Publication Date:
- 2020-12-23
- Subjects:
- bioluminescence -- COVID‐19 -- ELISA -- LuLISA -- SARS‐CoV‐2
Immunology -- Periodicals
616.079 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/eji.202049058 ↗
- Languages:
- English
- ISSNs:
- 0014-2980
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.730100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24677.xml